Metabolism Disorder TRIZ Cases

This prebiotic composition combines diverse fibers, seeds, herbs, and mushrooms to support gut bacteria and immune function.

Cyclic polypeptides mimic TNF-alpha's lectin-like domain to restore mutant ENaC sodium transport and improve salt balance in PHA type 1B.

This composition uses fermented-vegetable strains to reduce liver damage markers, triglycerides, cholesterol, and body fat.

Layered dosing separates metformin from linagliptin and empagliflozin, using stabilizers to maintain stability and controlled release.

Epigenetic modifiers enhance stem cell differentiation into functional beta cells.

Microporous annealed particle scaffolds support dissociated islet cell survival and function without in vitro preconditioning.

Sequential filtration and controlled shear produce stable chondrisome fractions that increase ATP production in recipient cells.

Defined ionic-liquid salt compositions help GLP-1 and amylin analogs cross mucosal barriers for metabolic disease treatment.

Mulberry leaf extract, fiber, and unsaturated fatty acids are taken with meals to reduce postprandial glucose and insulin spikes.

The formulation combines Lactobacillus strains, plant sterols, and Ashwagandha to support LDL and CRP reduction while maintaining stability.

A microRNA panel predicts statin intolerance before therapy, supporting personalized treatment.

This case uses PRL-1-overexpressing mesenchymal stem cells to address inadequate fat-accumulation treatments by inhibiting adipogenesis.

This case combines ibrutinib with mannitol, crospovidone, and functional excipients for high-load tablets and improved bioavailability.

Weekly tirzepatide dose escalation balances glycemic control with fewer gastrointestinal events.

This case uses inhibitory interneuron precursors in the hypothalamic arcuate nucleus to reduce glucose levels with fewer repeat treatments.

This case pairs mucin-degrading and butyrate-producing microbes to create conditions that increase engraftment abundance.

Phytochemical cross-linking creates biocompatible plant-protein particles for stable, sustained delivery of ketones and other supplements.

This case uses antibody-enzyme fusion proteins to target lysosomes, increase membrane permeability, and remove disease-associated cells.

A glucose-responsive copolymer matrix in microneedle patches releases insulin during hyperglycemia, eliminating electronic sensor failures.

A pro-drug peptide conjugates glucagon with basic amino acids to enhance aqueous solubility and chemical stability.

CXCR3 neutralizing antibodies bind specific receptor peptides to block inflammatory signaling pathways.

Oral dual GIP/GLP-1 receptor agonists extend duration of action to reduce dosing frequency while mitigating gastrointestinal side effects.

Antagonistic antibodies block VEGF-B signaling to accelerate wound closure, resolving slow healing in diabetic patients without affecting blood glucose levels.

Reconstituted high-density lipoprotein infusions increase cholesterol efflux capacity by 1.5 to 2.5 times in post-heart attack patients.

A GLP1-GDF15 fusion protein combines two distinct peptide pharmacologies into a single therapeutic molecule.

Hydrogel matrix combined with gastrin composition sustains islet cell viability and function in a supportive 3D environment.

A herbal composition reduces body weight and plasma lipids through specific ingredient proportions.

A glucose-sensitive insulin conjugate switches between inactive and active forms via competitive binding.

Plant extract composition promotes adipose thermogenesis through polyphenolic modulation, avoiding caffeine-induced cardiovascular and liver damage.

A dietary supplement combining fumaric acid with group B vitamins to normalize lipid metabolism.

Linagliptin demonstrates non-inferiority to glimepiride for glycemic control while reducing hypoglycemia risk in type 2 diabetes.

Engineered oxalate decarboxylase polypeptides degrade oxalate in the gastrointestinal tract, reducing kidney stone risk without dietary restrictions.

GP2, CD49d, and FOLR1 markers isolate PDX1+/NKX6-1+ pancreatic progenitor cells, resolving contamination risks in diabetes cell therapy.

NDX-90 peptide lowers ACE2 expression by reducing glucagon, addressing insufficient targeted therapies for coronavirus infections.

Combining cannabidiol with beta-hydroxybutyrate accelerates metabolic transition into ketosis while reducing keto flu symptoms.

Combining denatonium salts with GLP-1 agonists stimulates episodic gut peptide secretion to enhance weight loss efficacy.

An oral dosage form incorporates a drying agent to create a localized dry environment at the intestinal site.

Linking an immunoglobulin Fc region to the insulin beta chain via a non-peptidyl polymer extends duration, reducing administration frequency.

Sheep PDGFD variants reduce mRNA expression of adipogenic genes like CEBPα and PPARγ to limit fat deposition and improve meat quality.

Urea complexation enriches docosapentaenoic acid in free acid omega-3 compositions to lower triglycerides without raising LDL levels.

Enzymatic hydrolysis and chromatographic separation remove bitter-tasting aldose terminal sugars from dietary fiber, preserving original food flavor.

Empagliflozin treats type 2 diabetes by reducing oxidative stress and cardiovascular event risk via renal glucose excretion.

A process converts 3-methylselenopropionaldehyde with alkaline cyanide and bisulfite to produce 2-hydroxy-4-methylselenobutyric acid.

Carbohydrate-degrading enzymes replace mechanical separation to lower labor costs during ferritin isolation.

A fusion protein combining modified FGF19 and GLP-1 sequences extends therapeutic half-life while maintaining metabolic regulation.

Neublastin polypeptide activates GFRalpha3-RET signaling to restore blood flow and capillary density in ischemic tissues.

Supercritical CO2 extraction yields tangerine peel extract rich in flavonoids and terpenoids to regulate spleen and stomach functions for effective weight loss.

A method forms cross-linked polymer hydrogels using competitive ligand exchange between a displacing agent and a pre-complexed chelating agent.

A serum-free culture method produces brown adipocytes from pluripotent stem cells using specific cytokine cocktails.